Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Dhakal B, et al. Among authors: efebera y. Leukemia. 2020 Dec;34(12):3338-3347. doi: 10.1038/s41375-020-0830-0. Epub 2020 Apr 20. Leukemia. 2020. PMID: 32313109 Free PMC article.
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. de Souza JA, et al. Among authors: efebera y. Biol Blood Marrow Transplant. 2009 Sep;15(9):1094-9. doi: 10.1016/j.bbmt.2009.05.006. Biol Blood Marrow Transplant. 2009. PMID: 19660722 Free article.
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Efebera YA, et al. Biol Blood Marrow Transplant. 2010 Aug;16(8):1122-9. doi: 10.1016/j.bbmt.2010.02.015. Epub 2010 Feb 21. Biol Blood Marrow Transplant. 2010. PMID: 20178853 Free PMC article. Clinical Trial.
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Hamadani M, et al. Among authors: efebera y. Hematol Oncol. 2011 Dec;29(4):202-10. doi: 10.1002/hon.985. Epub 2011 Feb 28. Hematol Oncol. 2011. PMID: 21360728 Free PMC article.
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA. Jaglowski SM, et al. Among authors: efebera ya. Bone Marrow Transplant. 2014 Oct;49(10):1323-9. doi: 10.1038/bmt.2014.155. Epub 2014 Jul 28. Bone Marrow Transplant. 2014. PMID: 25068419 Free PMC article.
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. Salem G, et al. Leuk Lymphoma. 2015 Apr;56(4):1058-65. doi: 10.3109/10428194.2014.956314. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25166008 Free PMC article.
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. Girnius SK, et al. Br J Haematol. 2015 Apr;169(1):36-43. doi: 10.1111/bjh.13243. Epub 2015 Jan 8. Br J Haematol. 2015. PMID: 25572917 Free article. Clinical Trial.
Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA. Roddy JV, et al. Leuk Lymphoma. 2016;57(1):81-5. doi: 10.3109/10428194.2015.1045896. Epub 2015 Jul 3. Leuk Lymphoma. 2016. PMID: 26140610 Free PMC article.
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Efebera YA, et al. Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. doi: 10.1016/j.bbmt.2015.07.034. Epub 2015 Aug 6. Biol Blood Marrow Transplant. 2016. PMID: 26256940 Free PMC article. Clinical Trial.
128 results